Product Pipeline

Neratinib across the breast cancer therapy spectrum

	Phase I	Phase II	Phase III	Registration	Approval
HER2+ Breast Cancer					
Extended adjuvant *Neratinib monotherapy*	CONTROL ExteNET (Phase III HER2+ EBC*)			EAP/MAP	
Metastatic *Monotherapy or combo therapy*	FB-10: T-DM1 + neratinib NALA (Phase III 3rd Line HER2+ MBC**)				
Metastatic w/ brain mets *Monotherapy or combo therapy*	TBCRC-022				
HER2-mutant Breast Cancer/Solid Tumors					
Metastatic *Neratinib (± fulvestrant in MBC)*	SUMMIT- Breast HRC+ *** SUMMIT - Cervical SUMMIT - exon 18 mut NSCLC SUMMIT (Basket Trial)				

Copyright 2020 Puma Biotechnology

- EBC: Early breast cancer
- ** MBC: Metastatic breast cancer
- *** HRC+: Hormone receptor positive